GLOBAL OPHTHALMIC DRUGS MARKET 2023-2030

Lifesciences | Pharmaceuticals

GLOBAL OPHTHALMIC DRUGS MARKET 2023-2030

Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Regional Outlook | Forecast 2023-2030

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Ophthalmic drugs, including those for conditions like glaucoma, dry eye, retinal disorders, and infections, constitute a substantial segment of the pharmaceutical market. This industry's growth is due to several factors, one of them being the increasing prevalence of eye disorders globally. As the aging population grows and lifestyles evolve, the incidence of eye-related issues has surged, necessitating a corresponding rise in demand for effective pharmaceutical interventions. Thus, the global ophthalmic drugs market plays a pivotal role in addressing various eye disorders and diseases, contributing significantly to the overall healthcare landscape.

According to Triton Market Research’s report, the Global Ophthalmic Drugs Market was valued at $34547.84 million in 2022 and is expected to reach $58681.41 million by 2030, growing at a CAGR of 6.64% during the forecast period, 2023-2030. 


Click here to check out our blog on the Global Ophthalmic Drugs Market

MARKET PERFORMANCE: DRIVERS, CHALLENGES, AND OPPORTUNITIES

Factors such as innovations in drug delivery systems and advanced research drive the growth of the ophthalmic drugs market. This results in sustained-release implants and improved formulations that enhance treatment efficacy and patient compliance. Additionally, the development of biologics and gene therapies for ocular diseases represents a frontier of innovation within the industry. These advancements not only contribute to the expansion of treatment options but also foster collaborations between pharmaceutical companies and research institutions.

However, stringent regulatory requirements for drug approvals hampers the ophthalmic drugs market’s progress. These norms impede the swift introduction of new ophthalmic drugs to the market. Additionally, the high costs associated with research and development, coupled with the complexity of clinical trials, can pose financial challenges for smaller market players. Economic factors, such as reimbursement issues and the high cost of certain ophthalmic drugs, limit patient access, thereby affecting market growth.

Despite these challenges, an increase in approvals for innovative ophthalmic therapies presents a significant opportunity. This facilitates tailored treatments based on patient’s individual characteristics, such as their genetic makeup. Furthermore, the growing adoption of tele-ophthalmology and digital health technologies opens avenues for remote patient monitoring, early diagnosis, and improved accessibility to healthcare services, particularly in underserved regions.

Report scope can be customized per your requirements - Request Free Sample Report

KEY GEOGRAPHIES COVERED:

•         North America: United States and Canada

•         Europe: United Kingdom, France, Germany, Spain, Italy, Poland, and Rest of Europe

•         Asia-Pacific: China, Japan, India, Australia & New Zealand, South Korea, ASEAN Countries, and Rest of Asia-Pacific

•         Latin America: Brazil, Mexico, and Rest of Latin America

•         Middle East and Africa: Saudi Arabia, Turkey, United Arab Emirates, South Africa, and Rest of Middle East & Africa

SEGMENTATION ANALYSIS – OPHTHALMIC DRUGS MARKET:

•         Market by Type:

o        By Prescription Drugs

o        Over-The-Counter Drugs

•         Market by Condition:

o        Dry Eye

o        Glaucoma

o        Infection/Inflammation/Allergies

o        Retinal Disorder

•         Wet-Age Related Macular Degeneration

•         Dry-Age Related Macular Degeneration

•         Diabetic Retinopathy

•         Other Retinal Disorders

o        Other Conditions

Dry eye is a common eye disorder that occurs when the eyes do not produce enough tears. The symptoms may vary in severity from person to person. Common symptoms include dryness, burning or stinging, redness, blurred vision, sensitivity to light, watery eyes, and discomfort with contact lenses. It is prevalent in the North American population, where 5% to 30% of the adult population experiences dry eye symptoms.

•         Market by Therapeutic Type:

o        Anti-Glaucoma

o        Anti-Infection

o        Anti-Inflammatory

o        Anti-Allergy

o        Other Therapeutic Types

The anti-inflammatory therapeutic class comprises a group of medications specifically used to reduce eye inflammation. These medications formulated as ophthalmic solutions, eye drops, ointments, gels, or intraocular injections work by suppressing the inflammatory response within the eye tissues. By using anti-inflammatory medications, healthcare professionals aim to alleviate these symptoms, promote healing, and prevent further damage to the eye.

•         Market by Delivery Method:

o        Gels

o        Eye Solutions & Suspensions

o        Capsules & Tablets

o        Eye Drops

o        Ointments

•         Market by Channel:

o        Hospital Pharmacies

o        Drug Stores

o        Online Pharmacies

o        Other Channels

COMPETITIVE LANDSCAPE:

The competitive landscape helps dive into data about the key players in the ophthalmic drugs market. The strategic initiatives for each of the companies considered have been covered in detail.

Mergers & Acquisitions (December 2022):  Johnson & Johnson and Abiomed Inc

Johnson & Johnson completed its acquisition with Abiomed Inc. The latter operates as a standalone business within Johnson & Johnson’s MedTech segment. The completion of this acquisition allows Johnson & Johnson MedTech to expand its portfolio in the high-growth cardiovascular markets.

Product Launches (December 2022): Thea Pharma

Thea Pharma Inc announced the US Food and Drug Administration (FDA) approval for the New Drug Application (NDA) of IYUZEH™ (latanoprost ophthalmic solution) 0.005% for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).


KEY BENEFITS OF THE REPORT:

·       Triton Market Research has a collective experience of 25-30 years in the industry, with its analysts and experts encompassing the most infallible research methodology for its market intelligence and industry analysis.

·       Our research methodology helps in achieving a broader consensus of the market size, shape, and industry trends within each industry segment.

·       The strategy adopted in designing the research methodology includes the amalgamation of the information assembled from primary and secondary sources, with the assistance of analytical tools to construct the forecast and predictive models.

·       The scope of the market report comprises the current scenario of the global ophthalmic drugs market, along with the detailed overview of the industry outlook, market dynamics, segmentation analysis, regional outlook, and competitive landscape for the period 2023-2030.


FAQs:

Q 1) Which region holds the highest share in the global ophthalmic drugs market?

The North American region had the highest share of around 37% in 2022 in the global ophthalmic drugs market.

Q 2) What is one notable trend in the ophthalmic drugs market?

A noticeable trend is the rising adoption of over-the-counter (OTC) ophthalmic drugs due to their accessibility, contributing positively to the market’s revenue.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT
ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028
Lifesciences

ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028

Market by Type, Application, E ..

VIEW REPORT

Table of Content

1. GLOBAL OPHTHALMIC DRUGS MARKET - SUMMARY

2. INDUSTRY OUTLOOK

2.1. TECHNOLOGY SNAPSHOT

2.2. IMPACT ANALYSIS ON THE OPHTHALMIC DRUGS MARKET

2.2.1. COVID-19 IMPACT ON THE OPHTHALMIC DRUGS MARKET

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET MATURITY ANALYSIS

2.5. REGULATORY FRAMEWORK

2.6. KEY BUYING IMPACT ANALYSIS

2.7. KEY MARKET STRATEGIES

2.7.1. COLLABORATIONS

2.7.2. PRODUCT LAUNCHES

2.7.3. MERGERS & ACQUISITIONS

2.8. MARKET DRIVERS

2.8.1. AGING POPULATION VULNERABLE TO EYE DISORDERS

2.8.2. PROGRESS IN DRUG DELIVERY TECHNOLOGIES

2.8.3. ESCALATING INCIDENCE OF OCULAR DISEASES

2.8.4. REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS

2.9. MARKET CHALLENGES

2.9.1. CHALLENGING TIMELINES FOR PRODUCTS APPROVAL

2.9.2. ADVERSE EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE

2.10. MARKET OPPORTUNITIES

2.10.1. SURGE IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGS

2.10.2. INCREASE IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES

2.11. ANALYST PERSPECTIVE

3. GLOBAL OPHTHALMIC DRUGS MARKET – BY TYPE

3.1. PRESCRIPTION DRUGS

3.2. OVER-THE-COUNTER DRUGS

4. GLOBAL OPHTHALMIC DRUGS MARKET – BY CONDITION

4.1. DRY EYE

4.2. GLAUCOMA

4.3. INFECTION/INFLAMMATION/ALLERGIES

4.4. RETINAL DISORDER

4.4.1. WET-AGE RELATED MACULAR DEGENERATION

4.4.2. DRY-AGE RELATED MACULAR DEGENERATION

4.4.3. DIABETIC RETINOPATHY

4.4.4. OTHER RETINAL DISORDERS

4.5. OTHER CONDITIONS

5. GLOBAL OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE

5.1. ANTI-GLAUCOMA

5.2. ANTI-INFECTION

5.3. ANTI-INFLAMMATORY

5.4. ANTI-ALLERGY

5.5. OTHER THERAPEUTIC TYPES

6. GLOBAL OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD

6.1. GELS

6.2. EYE SOLUTIONS & SUSPENSIONS

6.3. CAPSULES & TABLETS

6.4. EYE DROPS

6.5. OINTMENTS

7. GLOBAL OPHTHALMIC DRUGS MARKET – BY CHANNEL

7.1. HOSPITAL PHARMACIES

7.2. DRUG STORES

7.3. ONLINE PHARMACIES

7.4. OTHER CHANNELS

8. GLOBAL OPHTHALMIC DRUGS MARKET – BY REGIONAL OUTLOOK

8.1. NORTH AMERICA

8.1.1. MARKET BY TYPE

8.1.2. MARKET BY CONDITION

8.1.2.1. MARKET BY RETINAL DISORDER

8.1.3. MARKET BY THERAPEUTIC TYPE

8.1.4. MARKET BY DELIVERY METHOD

8.1.5. MARKET BY CHANNEL

8.1.6. COUNTRY ANALYSIS

8.1.6.1. UNITED STATES

8.1.6.1.1. UNITED STATES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.1.6.2. CANADA

8.1.6.2.1. CANADA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2. EUROPE

8.2.1. MARKET BY TYPE

8.2.2. MARKET BY CONDITION

8.2.2.1. MARKET BY RETINAL DISORDER

8.2.3. MARKET BY THERAPEUTIC TYPE

8.2.4. MARKET BY DELIVERY METHOD

8.2.5. MARKET BY CHANNEL

8.2.6. COUNTRY ANALYSIS

8.2.6.1. UNITED KINGDOM

8.2.6.1.1. UNITED KINGDOM OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2.6.2. GERMANY

8.2.6.2.1. GERMANY OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2.6.3. FRANCE

8.2.6.3.1. FRANCE OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2.6.4. ITALY

8.2.6.4.1. ITALY OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2.6.5. SPAIN

8.2.6.5.1. SPAIN OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2.6.6. POLAND

8.2.6.6.1. POLAND OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2.6.7. REST OF EUROPE

8.2.6.7.1. REST OF EUROPE OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3. ASIA-PACIFIC

8.3.1. MARKET BY TYPE

8.3.2. MARKET BY CONDITION

8.3.2.1. MARKET BY RETINAL DISORDER

8.3.3. MARKET BY THERAPEUTIC TYPE

8.3.4. MARKET BY DELIVERY METHOD

8.3.5. MARKET BY CHANNEL

8.3.6. COUNTRY ANALYSIS

8.3.6.1. CHINA

8.3.6.1.1. CHINA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3.6.2. JAPAN

8.3.6.2.1. JAPAN OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3.6.3. INDIA

8.3.6.3.1. INDIA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3.6.4. SOUTH KOREA

8.3.6.4.1. SOUTH KOREA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3.6.5. ASEAN COUNTRIES

8.3.6.5.1. ASEAN COUNTRIES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3.6.6. AUSTRALIA & NEW ZEALAND

8.3.6.6.1. AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3.6.7. REST OF ASIA-PACIFIC

8.3.6.7.1. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.4. LATIN AMERICA

8.4.1. MARKET BY TYPE

8.4.2. MARKET BY CONDITION

8.4.2.1. MARKET BY RETINAL DISORDER

8.4.3. MARKET BY THERAPEUTIC TYPE

8.4.4. MARKET BY DELIVERY METHOD

8.4.5. MARKET BY CHANNEL

8.4.6. COUNTRY ANALYSIS

8.4.6.1. BRAZIL

8.4.6.1.1. BRAZIL OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.4.6.2. MEXICO

8.4.6.2.1. MEXICO OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.4.6.3. REST OF LATIN AMERICA

8.4.6.3.1. REST OF LATIN AMERICA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.5. MIDDLE EAST AND AFRICA

8.5.1. MARKET BY TYPE

8.5.2. MARKET BY CONDITION

8.5.2.1. MARKET BY RETINAL DISORDER

8.5.3. MARKET BY THERAPEUTIC TYPE

8.5.4. MARKET BY DELIVERY METHOD

8.5.5. MARKET BY CHANNEL

8.5.6. COUNTRY ANALYSIS

8.5.6.1. UNITED ARAB EMIRATES

8.5.6.1.1. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.5.6.2. TURKEY

8.5.6.2.1. TURKEY OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.5.6.3. SAUDI ARABIA

8.5.6.3.1. SAUDI ARABIA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.5.6.4. SOUTH AFRICA

8.5.6.4.1. SOUTH AFRICA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.5.6.5. REST OF MIDDLE EAST & AFRICA

8.5.6.5.1. REST OF MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

9. COMPETITIVE LANDSCAPE

9.1. ABBVIE INC

9.1.1. OVERVIEW

9.1.2. PRODUCT PORTFOLIO

9.1.3. KEY STRENGTHS

9.1.4. KEY CHALLENGES

9.2. BAUSCH HEALTH COMPANIES INC

9.2.1. OVERVIEW

9.2.2. PRODUCT PORTFOLIO

9.2.3. KEY STRENGTHS

9.2.4. KEY CHALLENGES

9.3. JOHNSON & JOHNSON

9.3.1. OVERVIEW

9.3.2. PRODUCT PORTFOLIO

9.3.3. KEY STRENGTHS

9.3.4. KEY CHALLENGES

9.4. NOVARTIS AG

9.4.1. OVERVIEW

9.4.2. PRODUCT PORTFOLIO

9.4.3. KEY STRENGTHS

9.4.4. KEY CHALLENGES

9.5. REGENERON PHARMACEUTICALS INC

9.5.1. OVERVIEW

9.5.2. PRODUCT PORTFOLIO

9.5.3. KEY STRENGTHS

9.5.4. KEY CHALLENGES

9.6. SUN PHARMACEUTICAL INDUSTRIES LTD

9.6.1. OVERVIEW

9.6.2. PRODUCT PORTFOLIO

9.6.3. KEY STRENGTHS

9.6.4. KEY CHALLENGES

9.7. ACCUTOME INC

9.7.1. OVERVIEW

9.7.2. PRODUCT PORTFOLIO

9.7.3. KEY STRENGTHS

9.7.4. KEY CHALLENGES

9.8. GENENTECH INC

9.8.1. OVERVIEW

9.8.2. PRODUCT PORTFOLIO

9.8.3. KEY STRENGTHS

9.8.4. KEY CHALLENGES

9.9. THEA PHARMA INC

9.9.1. OVERVIEW

9.9.2. PRODUCT PORTFOLIO

9.9.3. KEY STRENGTHS

9.9.4. KEY CHALLENGES

9.10. PFIZER INC

9.10.1. OVERVIEW

9.10.2. PRODUCT PORTFOLIO

9.10.3. KEY STRENGTHS

9.10.4. KEY CHALLENGES

10. RESEARCH METHODOLOGY & SCOPE

10.1. RESEARCH SCOPE & DELIVERABLES

10.2. SOURCES OF DATA

10.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: GLOBAL OPHTHALMIC DRUGS MARKET, BY REGIONAL OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: LIST OF COLLABORATIONS

TABLE 4: LIST OF PRODUCT LAUNCHES

TABLE 5: LIST OF MERGERS & ACQUISITIONS

TABLE 6: GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)

TABLE 7: GLOBAL OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)

TABLE 8: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

TABLE 9: GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)

TABLE 10: GLOBAL OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)

TABLE 11: GLOBAL OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)

TABLE 12: GLOBAL OPHTHALMIC DRUGS MARKET, BY REGIONAL OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 13: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 14: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)

TABLE 15: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)

TABLE 16: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

TABLE 17: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)

TABLE 18: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)

TABLE 19: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)

TABLE 20: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 21: EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)

TABLE 22: EUROPE OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)

TABLE 23: EUROPE OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

TABLE 24: EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)

TABLE 25: EUROPE OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)

TABLE 26: EUROPE OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)

TABLE 27: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 28: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)

TABLE 29: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)

TABLE 30: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

TABLE 31: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)

TABLE 32: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)

TABLE 33: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)

TABLE 34: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 35: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)

TABLE 36: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)

TABLE 37: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

TABLE 38: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)

TABLE 39: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)

TABLE 40: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)

TABLE 41: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 42: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)

TABLE 43: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)

TABLE 44: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

TABLE 45: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)

TABLE 46: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)

TABLE 47: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)

List of Figures

FIGURE 1: TECHNOLOGY SNAPSHOT

FIGURE 2: MARKET MATURITY ANALYSIS

FIGURE 3: GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2022 & 2030 (IN %)

FIGURE 4: GLOBAL OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS, 2023-2030 (IN $ MILLION)

FIGURE 5: GLOBAL OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS, 2023-2030 (IN $ MILLION)

FIGURE 6: GLOBAL OPHTHALMIC DRUGS MARKET, BY CONDITION, 2022 & 2030 (IN %)

FIGURE 7: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2030 (IN $ MILLION)

FIGURE 8: GLOBAL OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2030 (IN $ MILLION)

FIGURE 9: GLOBAL OPHTHALMIC DRUGS MARKET, BY INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)

FIGURE 10: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

FIGURE 11: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2022 & 2030 (IN %)

FIGURE 12: GLOBAL OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)

FIGURE 13: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)

FIGURE 14: GLOBAL OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY, 2023-2030 (IN $ MILLION)

FIGURE 15: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS, 2023-2030 (IN $ MILLION)

FIGURE 16: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER CONDITIONS, 2023-2030 (IN $ MILLION)

FIGURE 17: GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2022 & 2030 (IN %)

FIGURE 18: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2030 (IN $ MILLION)

FIGURE 19: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2030 (IN $ MILLION)

FIGURE 20: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY, 2023-2030 (IN $ MILLION)

FIGURE 21: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2030 (IN $ MILLION)

FIGURE 22: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC TYPES, 2023-2030 (IN $ MILLION)

FIGURE 23: GLOBAL OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2022 & 2030 (IN %)

FIGURE 24: GLOBAL OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2030 (IN $ MILLION)

FIGURE 25: GLOBAL OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS & SUSPENSIONS, 2023-2030 (IN $ MILLION)

FIGURE 26: GLOBAL OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS, 2023-2030 (IN $ MILLION)

FIGURE 27: GLOBAL OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2030 (IN $ MILLION)

FIGURE 28: GLOBAL OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2030 (IN $ MILLION)

FIGURE 29: GLOBAL OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2022 & 2030 (IN %)

FIGURE 30: GLOBAL OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES, 2023-2030 (IN $ MILLION)

FIGURE 31: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2030 (IN $ MILLION)

FIGURE 32: GLOBAL OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES, 2023-2030 (IN $ MILLION)

FIGURE 33: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER CHANNELS, 2023-2030 (IN $ MILLION)

FIGURE 34: GLOBAL OPHTHALMIC DRUGS MARKET, BY REGIONAL OUTLOOK, 2022 & 2030 (IN %)

FIGURE 35: UNITED STATES OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 36: CANADA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 37: UNITED KINGDOM OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 38: GERMANY OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 39: FRANCE OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 40: ITALY OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 41: SPAIN OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 42: POLAND OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 43: REST OF EUROPE OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 44: CHINA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 45: JAPAN OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 46: INDIA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 47: SOUTH KOREA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 48: ASEAN COUNTRIES OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 49: AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 50: REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 51: BRAZIL OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 52: MEXICO OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 53: REST OF LATIN AMERICA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 54: UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 55: TURKEY OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 56: SAUDI ARABIA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 57: SOUTH AFRICA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

FIGURE 58: REST OF MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET 2023-2030 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$2,750.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$4,000.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying